Drug intelligence / Profile preview

CHXM-003

Development stage: Preclinical
Lead developer: ChomiX Biotech
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

CHXM-003 is a small molecule targeted protein degradation (TPD) candidate being developed by ChomiX for the treatment of tumors. Leveraging ChomiX's proprietary chemoproteomics platform, the drug is designed to engage an E3 ubiquitin-protein ligase to facilitate the ubiquitination and subsequent proteasomal degradation of specific target proteins within tumor cells. This approach aims to address previously "undruggable" targets by removing the protein entirely rather than simply inhibiting its function. As of early 2024, CHXM-003 is in the hit identification stage of preclinical development.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)

Beyond the preview

Go deeper on CHXM-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHXM-003.

Explore the full profile